Literature DB >> 18929493

Insulin resistance, inflammation, and non-alcoholic fatty liver disease.

Herbert Tilg1, Alexander R Moschen.   

Abstract

Non-alcoholic fatty liver disease (NAFLD), the major cause of abnormal liver function in the western world, is often associated with obesity and diabetes. In obese individuals, fat accumulation in the abdominal region affects both lipid and glucose metabolism, and a liver loaded with fat is insulin resistant. Insulin resistance (IR) is often associated with chronic low-grade inflammation, and numerous mediators released from immune cells and adipocytes contribute to development of IR. Recent results showing an important role for these mediators in NAFLD are providing us with a better understanding of this highly prevalent disease with implications for novel therapy development. This review highlights new aspects in development of liver steatosis and the relevance of various cytokines and adipocytokines in NAFLD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18929493     DOI: 10.1016/j.tem.2008.08.005

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  148 in total

1.  Conjugated bile acid-activated S1P receptor 2 is a key regulator of sphingosine kinase 2 and hepatic gene expression.

Authors:  Masayuki Nagahashi; Kazuaki Takabe; Runping Liu; Kesong Peng; Xiang Wang; Yun Wang; Nitai C Hait; Xuan Wang; Jeremy C Allegood; Akimitsu Yamada; Tomoyoshi Aoyagi; Jie Liang; William M Pandak; Sarah Spiegel; Phillip B Hylemon; Huiping Zhou
Journal:  Hepatology       Date:  2015-03-09       Impact factor: 17.425

2.  Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis.

Authors:  Giovanni Targher; Lorenzo Bertolini; Stefano Rodella; Giuseppe Lippi; Giacomo Zoppini; Michel Chonchol
Journal:  Clin J Am Soc Nephrol       Date:  2010-08-19       Impact factor: 8.237

3.  PGRN induces impaired insulin sensitivity and defective autophagy in hepatic insulin resistance.

Authors:  Jiali Liu; Huixia Li; Bo Zhou; Lin Xu; Xiaomin Kang; Wei Yang; Shufang Wu; Hongzhi Sun
Journal:  Mol Endocrinol       Date:  2015-02-09

4.  PTEN in liver diseases and cancer.

Authors:  Marion Peyrou; Lucie Bourgoin; Michelangelo Foti
Journal:  World J Gastroenterol       Date:  2010-10-07       Impact factor: 5.742

Review 5.  Increased risk of cardiovascular disease and chronic kidney disease in NAFLD.

Authors:  Enzo Bonora; Giovanni Targher
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-08       Impact factor: 46.802

6.  Increased parenchymal damage and steatohepatitis in Caucasian non-alcoholic fatty liver disease patients with common IL1B and IL6 polymorphisms.

Authors:  J E Nelson; P Handa; B Aouizerat; L Wilson; L A Vemulakonda; M M Yeh; K V Kowdley
Journal:  Aliment Pharmacol Ther       Date:  2016-10-11       Impact factor: 8.171

7.  Lack of kinin B₁ receptor potentiates leptin action in the liver.

Authors:  Raphael Gomes Fonseca; Vicencia Micheline Sales; Eduardo Ropelle; Carlos Castilho Barros; Lila Oyama; Silvia Saiuli Iuki Ihara; Mário Jose Abdalla Saad; Ronaldo Carvalho Araújo; João Bosco Pesquero
Journal:  J Mol Med (Berl)       Date:  2013-02-06       Impact factor: 4.599

Review 8.  Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis.

Authors:  Suzanne M de la Monte; Lisa Longato; Ming Tong; Jack R Wands
Journal:  Curr Opin Investig Drugs       Date:  2009-10

Review 9.  Animal models of insulin resistance and heart failure.

Authors:  Mauricio Velez; Smita Kohli; Hani N Sabbah
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

10.  PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acid omega-Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver Disease.

Authors:  James P Hardwick; Douglas Osei-Hyiaman; Homer Wiland; Mohamed A Abdelmegeed; Byoung-Joon Song
Journal:  PPAR Res       Date:  2010-03-16       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.